SpaceX~$1TSpaceX~$1T
Insider Buying
Subscribe
All stock lists
ORKA

Oruka Therapeutics, Inc. (NASDAQ:ORKA)

US · Delayed Price · Currency is USD
Healthcare · Biotechnology
$95.81-$1.76 (-1.80%)
 
Market cap
$6.50B
Insider Score
Analyst consensus
Listed since
Aug 8, 1997
Market Cap$6.50B+220.8%
Revenue (ttm)n/a
Net Incomen/a-39.7%
EPSn/a+27.2%
Shares Out67.82M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume1,977,006
Open$95.74
Previous Close$97.57
Day's Range$93.42 - $96.80
52-Week Range$25.23 - $115.52
Betan/a
AnalystsBuy
Price Target$131.33(+37.07%)
Earnings Daten/a

About ORKA

Oruka Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel monoclonal antibody therapeutics for psoriasis (PsO), and other inflammatory and immunology (I&I) indications. Its lead products include ORKA-001 that targets p19 subunit of interleukin-23, which is in phase 2a trial for the treatment of PsO; and ORKA-002 that targets interleukin-17A and interleukin-17F, which is in phase 2 trial for the treatment of PsO, psoriatic arthritis, and other conditions. The company also develops ORKA-003 for targeting an undisclosed pathway; and ORKA-021, a sequential combination regimen of ORKA-002 and ORKA-001. Oruka Therapeutics, Inc. is headquartered in Menlo Park, California.

Address
855 Oak Grove Avenue, Menlo Park, CA, 94025, US
Market Cap
6.50 billion
Employees
68
Industrial Classification
Biotechnology

What Are Insiders Doing?

Open-market buy / sell balanceNet Selling
Sold
$4.50M
Bought
$0

View the trades behind this meter — each links to its SEC Form 4 →

Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.

Analyst consensus

Moderate Buy
4 Buy0 Hold0 SellAvg target $116.83 (+21.9%)

4 firms rating ORKA in the last 3 months, one vote each. Issuer-paid research is not counted.

1 Day
-1.80%
5 Days
-7.96%
1 Month
+18.07%
6 Months
+58.08%
1 Year
+220.76%

$ORKA stock is featured in our Insider Score Rankings, and Insider Trades datasets.

→ All Stock Lists

Recently reported changes in ORKA holdings by institutional investors

Scanning latest 13F filings…

Latest 0 13F filings · Source: SEC EDGAR

View all institutional owners →

Insider Trading

Quarterly net insider trading by ORKA's directors and management

Net Shares Purchased by Insiders−50k−25k02025Q42026Q12026Q22026Q32026Q4

Source: SEC EDGAR (Form 4)

Corporate Lobbying

ORKA Estimated quarterly lobbying spending

Source: U.S. Senate LDA

U.S. Patents

New ORKA patent grants

Loading patent grants…

Source: USPTO Open Data Portal

Government Contracts

Estimated quarterly amount awarded to ORKA from public contracts

Source: USAspending.gov

Top ETF Holders

ETFs with the largest estimated holdings in ORKA

XBIState Street SPDR S&P Biotech ETF$161.50M
VTIVanguard Morningstar Total Stock Market ETF$145.37M
IWMiShares Russell 2000 ETF$128.90M
VBVanguard Morningstar Small-Cap ETF$64.65M
VXFVanguard Extended Market ETF$62.60M
IWOiShares Russell 2000 Growth ETF$46.40M

Estimated from each fund’s disclosed top holdings × AUM

Bull Case vs Bear Case

AI-generated from ORKA’s recent data — informational, not investment advice

Generating analysis…

What’s Behind the Score

Insider Activity
48% of score
0
Analyst Ratings
32% of score
99
News & Sentiment
20% of score
62

News check: Positive Phase 2 psoriasis data and Q3 results balance concerns about valuation and insider selling activity.

Recent Insider Activity

Buys
0
Sells
22
Buy Value
$0
Distinct Buyers
0

Insider Score Trend Over Time

-32.0 since Aug 21
0255075100Aug 21 — Insider Score 32.0Aug 22 — Insider Score 33.0Aug 23 — Insider Score 33.0Aug 24 — Insider Score 33.0Aug 25 — Insider Score 33.0Aug 26 — Insider Score 33.0Aug 27 — Insider Score 33.0Aug 28 — Insider Score 33.0Aug 29 — Insider Score 33.0Aug 30 — Insider Score 33.0Aug 31 — Insider Score 33.0Sep 1 — Insider Score 0.0Sep 2 — Insider Score 0.0Sep 3 — Insider Score 0.0Sep 4 — Insider Score 0.0Sep 5 — Insider Score 0.0Sep 6 — Insider Score 0.0Sep 7 — Insider Score 0.0Sep 8 — Insider Score 0.0Sep 9 — Insider Score 0.0Sep 10 — Insider Score 0.0Sep 11 — Insider Score 0.0Sep 12 — Insider Score 0.0Sep 13 — Insider Score 0.0Sep 14 — Insider Score 0.0Sep 15 — Insider Score 0.0Sep 16 — Insider Score 0.0Sep 17 — Insider Score 0.0Sep 18 — Insider Score 0.0Sep 19 — Insider Score 0.0Sep 20 — Insider Score 0.0Sep 21 — Insider Score 0.0Sep 22 — Insider Score 0.0Sep 23 — Insider Score 0.0Sep 24 — Insider Score 0.0Sep 25 — Insider Score 0.0Sep 26 — Insider Score 0.0Sep 27 — Insider Score 0.0Sep 28 — Insider Score 0.0Sep 29 — Insider Score 0.0Sep 30 — Insider Score 0.0Oct 1 — Insider Score 0.0Oct 2 — Insider Score 22.0Oct 3 — Insider Score 0.0Oct 4 — Insider Score 0.0Aug 21Sep 12Oct 4

Composite Insider Score (0–100) recomputed on each scoring run from live SEC Form 4 data.

Frequently Asked Questions

Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.

ETFs that hold this stock

SBIOALPS Medical Breakthroughs ETF4.54%
XBIState Street SPDR S&P Biotech ETF1.72%
DWASInvesco Dorsey Wright SmallCap Momentum ETF1.62%
WDNAWisdomTree BioRevolution Fund1.33%
BBCVirtus Biotech Clinical Trials ETF1.13%
PCSGPolen 5Perspectives Small-Mid Growth ETF1.11%
TDNAT. Rowe Price Biotech ETF1.05%
TMEDT. Rowe Price Exchange-Traded Funds, Inc. - T. Rowe Price Health Care ETF1.02%
JSMLJanus Henderson Small Cap Growth Alpha ETF0.84%
MEDIHarbor Health Care ETF (MEDI)0.77%
SGRWHarbor Active Small Cap Growth ETF (SGRW)0.74%
CGMMCapital Group U.S. Small and Mid Cap ETF0.54%

Weight is the stock’s share of each fund’s holdings.